AbbVie Cuts Guidance; Bond Rout Draws Savers

The real reporting behind it

• Benzinga AbbVie Lowers FY2026 Adjusted EPS Guidance To $13.76-$13.96/Share, Q3 To $3.73-$3.77/Share, On $216M Acquired R&D And Milestone Expense
• Benzinga Lucid Produced 2,954 Vehicles And Delivered 3,806 Vehicles During Q3 2026
• MarketWatch Investors see big opportunity in ferocious 2026 bond-market rout
• Benzinga NeoGenomics Sees Q3 Revenue Of About $209M; Reiterates FY2026 Revenue, Adjusted EBITDA Guidance, Expects To Raise Revenue Guidance Midpoint On Q3 Call

Aired Oct 5, 2026, 4:21 PM ET on BBN. The anchors are fictional; their lines are written by AI. The headlines are real and belong to the outlets above. Not financial advice.